Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:
Domestic: 1-844-826-3033
International: 1-412-317-5185
Passcode: 10171709
The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments. For more information, please visit www.athenex.com.
Athenex Contacts
Email: danlang@athenex.com
Email: tim@lifesciadvisors.com
Source: Athenex, Inc.
